

**EUROPEAN
CURRICULUM VITAE
FORMAT**



PERSONAL INFORMATION

Name	CIRINO BOTTA
Address	VIA AGRIGENTO, 67, 90141, PALERMO (PA), ITALY
Telephone	
E-mail	cirino.botta@unipa.it
Nationality	ITALIAN
Date of birth	10/08/1985

BIOGRAPHICAL SKETCH

Cirino Botta is an Associate Professor of Hematology and the Head of the Experimental Hematology and Immunogenomics Lab at the University of Palermo. He graduated in medicine and surgery at the University of Siena in 2008 and specialized in medical oncology at the Magna Graecia University of Catanzaro in 2016, where he achieved his PhD in Translational Oncology in 2018. He has carried out research and clinical activities in several national and international centers, including the Clinica Universidad de Navarra and the Centro de Investigación Médica Aplicada (CIMA) in Spain and the Annunziata Hospital of Cosenza. He is an expert in multiple myeloma management as well as tumor and immune biology, single cell analysis, flow cytometry and bioinformatics. He is co-author of 90 scientific articles in peer-reviewed journals, with an h-index of 31 and 2545 citations. He has received several awards and recognitions for his scientific activity, such as the EHA award in 2018 and 2019, the AICC award in 2015, the ASH Abstract Achievement Award in 2013, and the FONICAP award in 2012. He is a reviewer for several scientific journals, such as European Journal of Cancer, International Journal of Cancer, Frontiers in Oncology, Scientific Report, and Blood Cancer Journal. From an academic point of view, he is in charge for teaching hematology at the degree course in medicine and the residency programs in hematology and medicine and palliative care at the University of Palermo. He has participated as an organizer, moderator or speaker at numerous national and international congresses and courses in the field of onco-hematology. He is involved as PI in several phase 2/3 clinical trials in multiple myeloma and received several research grants from national and European competitive call including PRIN PNRR 2022, the PRIN 2022, the Progetto Salute PNRR 2022 and the MFAG 2020.

WORK EXPERIENCE

- Dates (from – to) **April 2024/ at present**
- Name and address of employer **Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), University of Palermo, Palermo, Italy.**
- Type of business or sector **Hematology**
- Occupation or position held **Associate Professor of Hematology**

- Dates (from – to) **February 2023/ at present**
- Name and address of employer **Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), University of Palermo, Palermo, Italy.**
- Type of business or sector **Hematology**
- Occupation or position held **Head of Experimental Hematology and Immunogenomics Lab** which includes 2 Senior researchers, 1 clinician-researcher, 1 Post-Doc, 4 PhD student

- Dates (from – to) **April 2021/ April 2024**
- Name and address of employer **Unit of Hematology, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), University of Palermo, Palermo, Italy.**
- Type of business or sector **Onco-Hematology**
- Occupation or position held **Assistant Professor tenure-track (Ricercatore a tempo determinato tipo B MED/15)**

- Dates (from – to) **May 2019/ April 2021**
- Name and address of employer **Hematology Unit, Department of Onco-hematology, “Annunziata” Hospital of Cosenza**
- Type of business or sector **Onco-Hematology**
- Occupation or position held **Staff Physician/ Senior Researcher (Dirigente Medico a tempo indeterminato)**

- Dates (from – to) **May 2018/ May 2019**
- Name and address of employer **Clinica Universidad de Navarra/Centro de Investigación Médica Aplicada (CIMA) Prof. Jesus San Miguel/Dott. Bruno Paiva**
- Type of business or sector **Onco-Hematology**
- Occupation or position held **Visiting Fellow**

- Dates (from – to) **October 2016/ May 2019**
- Name and address of employer **“Magna Graecia” University of Catanzaro, Prof. Pierfrancesco Tassone**
- Type of business or sector **Onco-Hematology**
- Occupation or position held **Post-doc researcher (with clinical duties from October 2017)**

- Dates (from – to) **June 2011/ June 2016**
- Name and address of **“Magna Graecia” University of Catanzaro**

• employer • Type of business or sector • Occupation or position held	Medical Oncology Residency
• Dates (from – to) • Name and address of employer • Type of business or sector • Occupation or position held	2008/2011 Siena University Hospital Medical Oncology Fellowship at the Medical Oncology Unit and at Translational Oncology Lab
TEACHING EXPERIENCE • Dates (from – to) • Name and address of employer • Type of business or sector • Occupation or position held	October 2021 - ongoing University of Palermo Responsible of the teaching of Hematology within the Medicine and Surgery graduation course and within the Residency programs of “Hematology” and of “Medicine and Palliative Care” Associate Professor of Hematology
• Dates (from – to) • Name and address of employer • Type of business or sector • Occupation or position held	November 2019 Milano-Bicocca University Teacher within the course “Single Cell Analysis in the Era of Multidimensional Advanced Cytometry: Dissecting Heterogeneity of Immune System and Cancer Cells” for PhD students (Program in Translational and Molecular Medicine (Dimet)) Invited Professor
• Dates (from – to) • Name and address of employer • Type of business or sector • Occupation or position held	February 2019 Clinica Universidad de Navarra Teacher within the course “Investigación Traslacional en Medicina” for MD students Invited Professor
• Dates (from – to) • Name and address of employer • Type of business or sector • Occupation or position held	November 2017/ 2018 Magna Graecia” University of Catanzaro “Medical Oncology” course for Biotechnology undergraduate students Contract Professor (“Professore a Contratto”)
• Dates (from – to)	November 2017/ 2019

- Name and address of employer
Magna Graecia” University of Catanzaro
- Type of business or sector
Oncology
- Occupation or position held
Subject expert (“Cultore della Materia”) for “Medical Oncology” Teaching

EDUCATION AND TRAINING

- Dates (from – to)
July 2024
- Name and type of organisation providing education and training
CINECA/MIUR
- Principal subjects/occupational skills covered
Hematology
- Title of qualification awarded
National Scientific Qualification (ASN) as Academic Full Professor in Medical Oncology/Hematology/Reumatology
- Dates (from – to)
June 2020
- Name and type of organisation providing education and training
CINECA/MIUR
- Principal subjects/occupational skills covered
Technical and applied medicine
- Title of qualification awarded
National Scientific Qualification (ASN) as Academic Associate Professor in technical and applied Medicine
- Dates (from – to)
April 2018
- Name and type of organisation providing education and training
CINECA/MIUR
- Principal subjects/occupational skills covered
Hematology
- Title of qualification awarded
National Scientific Qualification (ASN) as Academic Associate Professor in Medical Oncology/Hematology/Reumatology
- Dates (from – to)
November 2015/ April 2018
- Name and type of organisation providing education and training
“Magna Graecia” University of Catanzaro, Catanzaro, Italy
- Principal
Translational Oncology

- subjects/occupational skills covered • Title of qualification awarded	<i>PhD in Translational Oncology</i> cum laude, with a dissertation entitled “MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma educated dendritic cells”
• Dates (from – to) • Name and type of organisation providing education and training • Principal subjects/occupational skills covered • Title of qualification awarded	June 2011/ June 2016 “Magna Graecia” University of Catanzaro, Catanzaro, Italy Medical Oncology <i>Specialty in Medical Oncology</i> (70/70 Magna cum laude, with a special mention for results obtained in the oncology research field) with a translational oncology dissertation entitled “Inflammation and Multiple Myeloma: preclinical evidence and new translational approaches”
• Dates (from – to) • Name and type of organisation providing education and training • Title of qualification awarded	February 2011 Siena University, Siena, Italy “Medicinae Doctor” Qualification
• Dates (from – to) • Name and type of organisation providing education and training • Title of qualification awarded	October 2004/ July 2010 Siena University, Siena, Italy Graduated in Medicine and Surgery (110/110 Magna cum laude) with a translational oncology dissertation on the “Immunological effects of Cetuximab in oncology”
• Dates (from – to) • Name and type of organisation providing education and training • Principal subjects/occupational skills covered • Title of qualification awarded	September 1999/ June 2004 “Liceo Scientifico E. Medi” High school, Battipaglia (SA), Italy Student High School Diploma (100/100)

**PERSONAL SKILLS
AND COMPETENCES**

*Acquired in the course of life
and career but not necessarily
covered by formal certificates
and diplomas.*

MOTHER TONGUE

OTHER LANGUAGES

- Reading skills
- Writing skills
- Verbal skills

- Reading skills
- Writing skills
- Verbal skills

CLINICAL SKILLS/RESEARCH

ITALIAN

ENGLISH

EXCELLENT

EXCELLENT

EXCELLENT

SPANISH

EXCELLENT

GOOD

EXCELLENT

- **Site PI** of the clinical trial AbbVie **M24-473** ““A Phase 2/3 Multicenter, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Etehtamig (ABBV-383) Compared to Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone (Dara-CyBorD) in Subjects with Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis”. (Abbvie)
- **Site PI** of the clinical trial 79635322MMY3004 **TRILOGY-7** “A Phase 3 Randomized Study Comparing JNJ-79635322 plus Daratumumab versus an Investigators Choice of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) or Daratumumab, Lenalidomide and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy”. (JNJ)
- **Site PI** of the clinical trial 79635322MMY2001 **TRILOGY-3** “A Phase 2, Open-label Study of JNJ-79635322 in Participants with Relapsed or Refractory Multiple Myeloma (RRMM) who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody”. (JNJ)
- **Site PI** of the clinical trial **DREAMM-10** – “A Phase 3, randomized, open-label study of belantamab mafodotin administered in combination with lenalidomide and dexamethasone (BRd) versus daratumumab, lenalidomide, and dexamethasone (DRd) in participants with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation (TI-NDMM)”
- **Site PI** of the Observational clinical study “BLENREP Dosing in Multiple Myeloma (**BEAMM-2-EAP**) – A retrospective chart review study of belantamab mafodotin combination therapies among patients with multiple myeloma from first relapse (2L+) (GSK)
- **Site PI** of the clinical trial “**MagnetisMM-16**: An International, Multicenter, Non-Interventional Post-Authorization Safety Study (PASS) to Evaluate the Effectiveness and Safety of Elranatamab in Patients with

Relapsed/Refractory Multiple Myeloma (RRMM) Treated in Real-World (RW) Settings”

- Site PI of the clinical trial CA0581019-ALUMMINATE – “A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)” BMS
- **Site PI** of the clinical trial **EFC15951-IRAKLIA**: “a randomized non-inferiority Phase 3 study evaluating subcutaneous versus intravenous administration of isatuximab in combination with pomalidomide and dexamethasone in adult RRMM patients “ (Sanofi-Aventis)
- **Site PI** of the clinical trial **C1071032-magnetisMM-32** – “a phase 3, open-label study of elranatamab monotherapy versus elotuzumab, pomalidomide, dexamethasone (epd) or pomalidomide, bortezomib, dexamethasone (pvd) or carfilzomib, dexamethasone (kd) in participants with relapsed/ refractory multiple myeloma who received prior anti-cd38 directed therapy” (Pfizer)
- **Site PI** of the Observational clinical study “**C1071025-MUST**: Multiple Myeloma Italian ObServational sTudy (MUST)” (Pfizer)
- **Subinvestigator and local coordinator** of the clinical trial **C1071006-magnetisMM-6**: “an open-label, 2-arm, multicenter, randomized phase 3 study to evaluate the efficacy and safety of elranatamab (PF-06863135) + daratumumab + lenalidomide versus daratumumab + lenalidomide + dexamethasone in transplant- ineligible participants with newly-diagnosed multiple myeloma” (Pfizer)
- **Site PI** of the clinical trial **64007957MMY3006 – MajesTEC-9** “A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide” (JNJ)
- Site PI of the clinical trial 64407564MMY3008 MonumenTAL-5 “A Phase 3 Study Comparing Talquetamab to Belantamab Mafodotin in Participants with relapsed/refractory multiple myeloma who have Received at least 4 Prior Therapies Including an Immunomodulatory Drug, a Proteasome Inhibitor, and an anti-CD-38”
- Subinvestigator clinical trial CINC280A2201 "A phase II, multicenter, study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non- small cell lung cancer (NSCLC)", Sponsor: Novartis pharmaceuticals
- Subinvestigator LSK37064 AM301-NCT03042611 (LSK) fase III apatinib vs placebo in advanced gastric cancer, Sponzor : LSK
- Design of several clinical trials including :phase 1 (TSPP/VAC-1, EUDRACT: 2009-016897-33; EUDRACT: 2017-002615-33), phase 2 (BEVA2007, EUDRACT: 2008-006051-40; GILFICET, EUDRACT: 2009-016454- 40) and phase 3 (GOLF-IG2, EUDRACT: 2005-003458-81).
- ICH GOOD CLINICAL PRACTICE E6 (R2) (April 2022)
- ALS certification, according to ILCOR 2015 guidelines (December 2017)

LABORATORY SKILLS AND COMPETENCES

Single Cell RNAseq/CITEseq analysis; Flow Cytometry, including Next generation flow cytometry with MRD detection Bioinformatic analysis with R; Cell lines and primary cells culture; T-Lymphocytes, Natural killer cells and Dendritic cells differentiation and colture Cell transfection (stable and transient) Proliferation assays

	Apoptosis assay Immunofluorescence Western Blot qRT-PCR ELISA assay Eli-Spot assay
TECHNICAL SKILLS AND COMPETENCES <i>With computers, specific kinds of equipment, machinery, etc.</i>	OS: WINDOWS; LINUX DISTRIBUTIONS SUCH AS UBUNTU; OSX . APPLICATION SOFTWARE: OFFICE SUITES; PHOTOSHOP; PAINT.NET. FLOW CYTOMETRY SOFTWARE: FLOWING SOFTWARE, CELLQUEST, DIVA, FLOWJO, FCS-EXPRESS STATISTICAL SOFTWARE: GRAPHPAD PRISM, SPSS, STATA, R, PYTHON
RESEARCH AREA	Clinical and Preclinical research in the field of tumor immuno-biology and personalization of cancer treatment. At present, I'm focused on the study of tumor microenvironment (T lymphocytes, monocytes, myeloid derived suppressor cells) at single cell level, by combining different techniques (flow cytometry, single cell RNAseq, TCR seq) and on the development of new methods for data integration in R
PEER REVIEWER ACTIVITY	European Journal of Cancer (ISSN: 0959-8049; IF: 6,680), International Journal of Cancer (ISSN: 1097-0215; IF: 4,982), Frontiers in Oncology (ISSN: 2234943X; IF:4,137), Scientific Report (ISSN: 2045-2322; IF: 4, 011), Expert Opinion on Biological Therapy (ISSN: 1744-7682; IF: 3,585), Life Sciences (ISSN: 0024-3205; IF:3.448), World Journal of Gastroenterology (ISSN:2219-2840; IF:3.411), Journal of Functional Foods (ISSN: 1756-4646; IF:3,197), European Journal of Pharmacology (ISSN: 0014-2999; IF: 3,17), Experimental and molecular pathology (ISSN: 0014-4800; IF:2,350), Blood Advances (ISSN: 2473-9537) and Journal of Cancer Therapy (ISSN:2151-1942) Member of the following scientific society: EHA, SIE, SIES
Page 8 - Curriculum vitae of [BOTTA, Cirino]	For more information go to www.cedefop.eu.int/transparency/ europa.eu.int/comm/education/index_en.html eurescv-search.com/

	AWARDS EHA award 2019 for the research “single-cell characterization of the multiple myeloma (MM) immune microenvironment identifies CD27- t cells as potential source of tumor-reactive lymphocytes” EHA award 2018 for the research “A new humanized monoclonal antibody against a specific glycosylated epitope of CD43 antigen for the therapeutic targeting of acute lymphoblastic leukemia T (T-ALL)” AICC award 2015 for the best poster with the research “Transcriptome profiling reveals anti-inflammatory activity of miR-29b in myeloma-associated dendritic cells” ASH “Abstract Achievement Award” 2013 for the research “Synthetic MiR-29b Mimics Potentiate Dendritic-Cell Based Immunotherapy Against Multiple Myeloma In Vitro and In Vivo” FONICAP 2012 award in memory of “Giovanni Garotti” for the research entitled “Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients” during the FONICAP meeting 2012 in Verona.
PARTICIPATION IN MEETING AS ORGANIZER, MODERATOR OR SPEAKER	“MultipleMyeloma2025”, Palermo, October 2025, Organizer “MultipleMyeloma2023”, Palermo, 21-22 September 2023, Organizer “MMTarget Young Hematologists: sharing real life experiences”, Naples, 30 June 2023, Speaker “Training post ASCO ed EHA 2023” dedicated to Pfizer Medical Direction, 27 June 2023, Speaker “MMuch Better: ottimizzare la gestione terapeutica del paziente affetto da Mieloma Multiplo, corso ECM ”, Speaker, 10 May/20 November 2023 “EmaTalk: caso clinico mieloma multiplo recidivato e refrattario” 25 May 2023, <i>Speaker</i> “Advisory Board Il paziente affetto da mieloma multiplo: gestione della malattia e qualità della vita” 15 May 2023, <i>Advisory Board Member</i> “MasterClass in Multiple Myeloma Percorso di formazione ECM”, Milan 27 April 2023, <i>Organizer and Speaker</i> “IMMstagram: I risvolti dell’innovazione nel MM nella pratica clinica e nella vita dei pazienti” Rome, 14-15 April 2023, <i>Speaker</i>

“Advisory Board Il ruolo di Elranatamab nel trattamento del paziente affetto da mieloma multiplo: dai dati preliminari nel setting TCR alle prospettive di sviluppo future” Rome, 17 MAR 2023, *Advisory Board Member*

“2° convegno regionale SIE 2023- delegazione sicilia” 06-07 February 2023, *Speaker*

“Advisory Board MIELOMA – Sud” 01 February 2023, *Advisory Board Member*

“Advisory Board: Management del paziente con mieloma multiplo recidivante refrattario: la pratica clinica siciliana” 23 November 2022, *Advisory Board Member*

“1° convegno regionale sie 2022- delegazione sicilia” 27-28 October 2022, *Speaker*

“SOHOITALY – 4th italian conference” 23-26 October 2023, Rome, *Speaker*

“49° Congresso Nazionale SIE”, Rome, September 26-28 2022 “low-dose ct-based bone marrow radiomic analysis for classification and outcome prediction in patients with multiple myeloma” *Speaker*

“European Society for Clinical Cell Analysis (ESCCA) Meeting 2022”, 21-24 September 2022, *Speaker*

“FSC verso mmunits: l'importanza della gestione efficace del paziente affetto da mieloma multiplo: approccio multidisciplinare” 20 APR 2022 - 30 JUN 2022 *Speaker*

FAD “Highlights dai Congressi ASCO -EHA - Focus su MM” – 2022 June 2022, *Speaker*

“Multiple Myeloma Forum - Gruppo di lavoro in tema di : Il ruolo dell'immunoterapia nel trattamento dei pazienti affetti da Mieloma Multiplo” 24-21 Giugno 2022, *Speaker*

“VI ISCCA (Italian Society for Cytometric Cell Analysis) meeting 2022”, 25-27 May 2022, Catania, *Speaker*

“FAD Sincrona Recenti updates e approcci traslazionali nel mieloma multiplo”, 10/17 May 2022, *Organizer*

“Advisory Board Macroregionale Sud Mieloma”, 24 February 2022, *Advisory Board Member*

“Novel translational approaches in hematological malignancies: from bench to bedside” Catania 5-6 November 2021 “How to track

microenvironment dysregulation in Multiple Myeloma: implications for guiding personalized medicine" *invited speaker*

"48° Congresso Nazionale SIE - 16° Congresso Nazionale SIES", Milan, October 24-27 2021 "Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in frontline therapy for patients not eligible for transplant" *oral abstract presentation*

"XVI. Multiple myeloma & IV. Cell therapy workshop" in Ostrava, Czech Republic (October 14-15, 2021), "Microenvironment dysregulation in multiple myeloma: novel challenges and therapeutic opportunities" *speaker*

"Conciliare i modelli gestionali del post pandemia con l'evoluzione delle terapie in onco-ematologia", Catanzaro, 19-20/11/2020; "il clinico davanti alla recidiva biochimica e alla recidiva clinica" *speaker*

"Multiple Myeloma and Related Malignancies, 5th Edition" BARI (ITALY), NOVEMBER 5-7, 2020; "Single cell characterization of MM immune microenvironment", *speaker*

"Ematologia. Approcci terapeutici a confronto", 07/02/2020 - 08/02/2020, Cosenza, Italy. "Terapia del Mieloma Multiplo Recidivato Refrattario". *Speaker*

"In vivo modelling of hematological malignancies: from bench to bedside" 31/1/2020 – 01/02/2020, Catania, Italy. "Novel techniques in flow cytometry" *Speaker*

"61st American Society of Hematology" annual meeting, 7-10/12/2019, Orlando, USA. With the work: "Single-Cell Characterization of the Multiple Myeloma (MM) Immune Microenvironment Identifies CD27-Negative T Cells As Potential Source of Tumor-Reactive Lymphocytes" *Speaker*

"What's next in Multiple Myeloma", 23/09/2019, Catania, Italy. "Immune cells in multiple myeloma: MDSC and T-cell subpopulations" *Speaker*

"17th International Myeloma Workshop (IMW)", 12-15/19/2020 Boston USA. Selected speaker with the work: "Single Cell Characterization of MM Immune Microenvironment Identifies CD27- Negative T Cells as Potential Tumor Reactive Lymphocytes" *Speaker*

"EHA 2019", Amsterdam 13-15/06/2019, *Selected Speaker* with the work: "single-cell characterization of the multiple myeloma (MM) immune microenvironment identifies CD27- t cells as potential source of tumor-reactive lymphocytes". *Speaker*

"An International multidisciplinary meeting Non-Small-Cell-Lung Cancer under the siege of immunotherapy and translational Oncology From the standard care to immuno-therapy and translational paths and 4th International cancer vaccine meeting" Reggio Calabria, Italy, 2-

4/11/2017, *Organizer and Speaker*

“The future of cancer therapy: the genome editing era” Magna Graecia University of Catanzaro, 8-9/06/2017. *Organizer*

“Comunicare la scienza”, Magna Graecia University of Catanzaro, 27/05/2016. *Organizer*

“Immunotherapy meets lung cancer: new treatments for non small cell lung cancer and 3rd international cancer vaccine meeting”, monteriggioni (si), 8-10/04/2016. *Organizer and Speaker*

“bio-therapeutics and personalized medicine – bioasia 2014”, hyderabad, India, 18-19/02/2014. *Moderator*

“55th congresso sic understanding onc-omics for patient-tailored cancer therapy” Copanello, Italy, 23-26/09/2013. *Speaker*

“percorsi di diagnosi e terapia nel carcinoma ovarico”, Magna Graecia University of Catanzaro, 27/03/2013. *Speaker*

PARTICIPATION IN RESEARCH PROGRAMS

- Ricerca Finalizzata 2024 GR-2024-12377752 “IMunological and tumor-based strategies for Predicting Undetectable minimal residual disease in Multiple Myeloma patients receiving immunotherapy” – **P.I. Cirino Botta Fund granted: 225.00,00 €**
- Pfizer External Research & Grants: grant 97508515 titled “Bringing care where they care: Better at Ho(MM)le!” – **P.I. Cirino Botta Fund granted: 74.268,81 \$**
- Oncopeptide research support for investigational experiments on NK-redirecting agents in multiple myeloma: **P.I. Cirino Botta Fund granted: 32.00,00 €**
- PRIN PNRR 2022 P2022E2JSK - Identification of Multiple Myeloma cell vulnerabilities to NK cell-mediated immunosurveillance (MM-LiNK) - **Unit P.I. Cirino Botta, Fund granted: 118.500,00 €**
- PRIN 2022 20229JM25N - Targeting the replicative and oxidative stress machinery to activate immune response against multiple myeloma (iMMuneRedOx) – **P.I. Cirino Botta, Fund granted: 105.300,00 €**
- Progetto Salute PNRR 2022, PNRR-MAD-2022-12376660 - Integrative multi-omics analysis to predict monoclonal gammopathies clinical evolution – **Unit P.I. Cirino Botta, Fund granted: 301.740,00 €**
- MFAG 2020 - ID. 24534 project Single cell characterization of bone marrow microenvironment and gut microbiota along myeloma onset and evolution – **P.I. Cirino Botta, Fund granted: 499.860,00 €**
- “SPECIAL PROGRAM FOR MOLECULAR CLINICAL ONCOLOGY– AIRC 5 PER MILLE” NO. 9980, 2010/15 (PI: P. TASSONE);
- “AIRC 5 PER 1000 MOLECULAR CLINICAL ONCOLOGY EXTENSION

PROGRAM" NO. 9980, 2016/18 (PI: P. TASSONE);

- "INNOVATIVE IMMUNOTHERAPEUTIC TREATMENTS OF HUMAN CANCER" MULTI UNIT REGIONAL NO. 16695 (COFINANZIATO DA AIRC E FONDAZIONE CARICAL), 2015/18 (PI: P. TASSONE).

BIBLIOMETRIC INDICATORS (SCOPUS)

Documents: 117
Citations: 3667
h-index: 36

PUBLICATIONS

1. Aquilina C, Romano A, Corsale AM, Biondo M, Speciale M, Tofacchi E, Di Simone M, Gigliotta E, Dieli C, Avellone C, Toscano A, Camarda L, Romano A, Cambria D, Giavaresi G, Raimondi L, Neri A, Campana S, Caccamo N, Dieli F, Siragusa S, Meraviglia S, **Botta C**. **"Coevolution of NK and Tumor Cell States Along Multiple Myeloma Progression from Precursor Conditions."** Int J Mol Sci. 2026 May 22;27(11):4682. doi: 10.3390/ijms27114682.
2. Touzeau C, Mina R, Quach H, Hungria V, Bhutani D, Chen W, Kumar S, Chaulagain C, Dimopoulos MA, Bahlis NJ, Maral S, van de Donk NWCJ, Schmidt Filho J, Saja K, Teipel R, Ando M, Roeloffzen W, Annibali O, Augustson B, **Botta C**, Delforge M, Bourgeois E, Buda G, Hus M, Perrot A, Preis M, Beksac M, Pour L, Farmer S, Nunes M, Oriol A, Melchardt T, Hu Y, Flogegård M, Wang D, Pei L, Wroblewski S, Ariës IM, Quijano Cardé NA, Perova T, de Jager T, Yeh TM, Vanquickenberghe V, Shah P, Chastain K, Kobos R, Carson R, Landgren O; MajesTEC-9 Trial Investigators. **"Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy."** N Engl J Med. 2026 May 29. doi: 10.1056/NEJMoa2603870.
3. Cambria D, Cannizzaro MT, Parrinello NL, Marino S, Dulcamare I, Puccio N, Torricelli F, Lionetti M, Calvo D, Khosropoor M, Conticello C, Di Raimondo F, Raimondi L, Giavaresi G, **Botta C**, Neri A, Romano A. **"FcyRIIIA Genotype in Plasma Cell Dyscrasias Is Associated with Clinical Progression, Bone Disease Extension and Immune Dysfunction."** Cancers (Basel). 2026 Mar 26 doi: 10.3390/cancers18071084
4. **Botta C**, Colombo GL, Di Matteo S, Martinotti C, Fogliati EL, Bruno GM, Novelli G, Di Virgilio R, Veggia B, Galimberti S. **"Cost-Effectiveness of Elranatamab Versus Teclistamab for the Management of Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma in Italy."** Cancers (Basel). 2026 Mar 25;18(7):1070. doi: 10.3390/cancers18071070.
5. Gullà A, Dhodapkar MV, Einsele H, Raab MS, Solimando AG, **Botta C**, Turi M, Sester LS, Portuguese AJ, Steinbrunn T, Anderson KC. **"Rethinking Multiple Myeloma Treatment: The Biological and Clinical Insights Guiding Immune-Based Combinations"**. Blood

- Cancer Discov. 2026 Mar 4;7(2):176-194. doi: 10.1158/2643-3230.BCD-25-0107.
6. Garofano F, Corsale AM, Biondo M, Romano A, Schmidt-Wolf I, Gullà AM, Siragusa S, **Botta C**. **"Identification of CD320, SLC44A1 and TNFRSF13B as potential novel therapeutic targets for CAR T-cell therapy in multiple myeloma."** Front Med (Lausanne). 2026 Jan 13 doi: 10.3389/fmed.2025.1737919.
 7. Mina R, Antonioli E, Barilà G, Bolli N, **Botta C**, Furlan A, Liberatore C, Martello M, Moré S, Oliva S, Rossini B, Saraci E, Solimando AG, Storti P, Zamagni E. **"Undetectable Minimal Residual Disease in Multiple Myeloma: Bridging the Gap Between Clinical Trials and Real-life Application"** Clin Lymphoma Myeloma Leuk. 2026 Mar;26(3):154-168. doi: 10.1016/j.clml.2025.12.016
 8. Corso A, Marchetti M, Galli M, Barilà G, Conticello C, Belotti A, Antonioli E, **Botta C**, Bringhen S, Cafro AM, Cea M, Derudas D, Furlan A, Gentile M, Giuliani N, Crimi F, Esposito A, Mancini P, Zacchino M, Frittoli B, Gozzetti A, Liberatore C, Mangiacavalli S, Mannina D, Rago A, Mele G, Montefusco V, Offidani M, Patriarca F, Pescosta N, Petrucci MT, Ria R, Tosi P, Vincelli D, Buda G, Zamagni E, di Toritto TC, Zambello R. **"Imaging in Plasma-Cell Neoplasms: Italian Experts' Recommendations"**. Eur J Haematol. 2026 May doi: 10.1111/ejh.70111
 9. Busà R, Panarello G, Gallo A, Miceli V, Castelbuono S, Sorrentino MC, Amico G, Carcione C, Russelli G, Cuscino N, Miele M, Timoneri F, Di Bella M, Zito G, Barbera F, Badami E, Corsale AM, Shekarkar Azgomi M, Conaldi PG, **Botta C**, Bulati M. **"Immune-Based Biomarkers as Predictors of Mortality in ECMO Therapy for Severe COVID-19 ARDS: Insights from a Retrospective Study."** Int J Mol Sci. 2025 Dec 30;27(1):390. doi: 10.3390/ijms27010390.
 10. Corsale AM, Azgomi MS, Gigliotta E, Di Simone M, Pacelli P, Cioffi F, Bestoso E, Raspadori D, Gozzetti A, Solimando A, Tabares P, Beilhack A, Speciale M, Corsale G, Sciortino M, Aquilina C, Brucato F, Cea M, Zambello R, Garofano F, Biondo M, Buffa F, Caccamo N, Dieli F, Meraviglia S, Siragusa S, **Botta C**. **"Bone marrow immune cell composition reflects multiple myeloma progression and affects treatment response."** Blood Neoplasia. 2025 Oct 16;3(1):100174. doi: 10.1016/j.bneo.2025.100174.
 11. Tulone G, Pavan N, Giaimo R, Martorana A, Salvaggio G, Cutaia G, Claps F, Gigliotta E, Marmo D, Minasola C, Siragusa S, Simonato A, **Botta C**. **"Monoclonal Gammopathy Prevalence in Newly Diagnosed Prostate Cancer Patients: A Correlative Perspective Observational Study."** Cancers (Basel). 2025;17(23):3790. doi: 10.3390/cancers17233790.
 12. **Botta C**, Corsale AM, Cammarata C, Di Fazio F, Gigliotta E, Rizzuto A, Ingrassi M, Speciale M, Aquilina C, Biondo M, Romano A, Napolitano M, Mattana M, Siragusa S. **"Inflammatory Biomarkers for Thrombotic Risk Assessment in Multiple Myeloma Patients on IMiD/aCD38-Based Regimens: Insights from a Prospective Observational Study."** Biomolecules. 2025 Oct 31;15(11):1533. doi: 10.3390/biom15111533.
 13. Conticello C, Del Fabro V, Romano A, Mele A, Mina R, Bringhen S,

- Orofino A, Antonioli E, Pulini S, De Paoli L, Za T, Cotzia E, Elia F, Casson A, Prete E, Citiso S, Liberatore C, Margiotta-Casaluci G, Fazio F, Morè S, Attucci I, Accardi F, Bongarzoni V, Mangiacavalli S, Rossi E, Mannina D, Garibaldi B, Rizzi R, Di Cecca M, Rossini B, Uccello G, **Botta C**, Leotta D, Vincelli D, Gentile M, Piciocchi A, Marsili G, Patriarca F, Zambello R, Musto P, Boccadoro M, Offidani M, Petrucci MT, Di Raimondo F. **“Continuous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) Italy.”** Ann Hematol. 2025 Oct;104(10) doi: 10.1007/s00277-025-06602-9
14. De Novellis D, Palmieri S, Rocco S, Derudas D, Della Pepa R, Roccotelli D, Esposito D, Masucci C, Gigliotta E, Barone ML, Morelli E, Lazzaro A, Bianco R, Accardi F, Marano L, Bonanni M, Della Corte AM, Serio B, Urciuoli E, Rizzo M, Fontana R, Arcamone M, Iula R, Dandolo A, Leone A, Rascato MG, Di Perna M, Falcone AP, Morello L, Marcacci G, Rodolfo NG, Frigeri F, Califano C, Carella AM, Risitano AM, Annunziata M, Pane F, Giudice V, **Botta C**, Selleri C. **“An Italian real-world multicenter study of patients with refractory/relapsed functional high-risk multiple myeloma patients treated with second-line therapies.”** Ann Hematol. 2025 Sep;104(9):4749-4757. doi: 10.1007/s00277-025-06572-y
 15. Susca N, Borrelli P, **Botta C**, Solimando AG. **“Prognostic impact of the immune microenvironment in multiple myeloma: a meta-analysis of current studies”.** Haematologica. May 15, 2025. doi:10.3324/haematol.2024.286264
 16. Desantis V, Andriano A, Düking T, Hartwig O, Ingravallo G, Biondo M, **Botta C**, Ria R, Vacca A, Solimando AG. **“Spatial imaging unlocks the potential of charting multiple myeloma and extramedullary disease.”** J Hematol Oncol. 2025;18(1):47. doi:10.1186/s13045-025-01699-x
 17. Chiarenza A, Aluisio GV, Parrinello NL, Marino S, Corsale AM, Privitera GF, Azgomi M, La Spina E, Cambria D, Curtopelle A, Isola G, **Botta C**, Di Raimondo F, Romano A, Santagati M. **“BNT162b2 mRNA vaccination affects the gut microbiome composition of patients with follicular lymphoma and chronic lymphocytic leukemia.”** Biomark Res. 2025 Feb 10. doi:10.1186/s40364-025-00734-w
 18. Martino EA, Derudas D, Rossi E, Stefanoni P, Mangiacavalli S, Zamagni E, Offidani M, Furlan A, Quinto AM, Della Pepa R, Bertuglia G, Barbieri E, Conticello C, De Magistris C, Bongarzoni V, Cafro AM, Mele A, **Botta C**, Sgherza N, Mele G, Annibali O, Rago A, Fontana R, Vigna E, Bruzzese A, Mancuso K, Amendola A, Citro A, Cotzia E, Morè S, Rivolti E, Pettine L, Galli M, De Stefano V, Petrucci MT, Corso A, Neri A, Di Raimondo F, Bolli N, Musto P, Morabito F, Gentile M **“Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study.”** Hematol Oncol. 2025;43(2):e70042. doi:10.1002/hon.70042
 19. De Pasquale C, Drommi F, Calabrò A, **Botta C**, Sidoti Migliore G,

- Carrega P, Vento G, Gaeini A, Pezzino G, Freni J, Bonaccorsi I, Vitale M, Filaci G, Fenoglio D, Iemmo R, Costa G, Cavaliere R, Ferlazzo G, Campana S. **"BNT162b2 COVID-19 vaccination elicits the expansion of CD16+CD8+ T cells endowed with Natural Killer cell features."** *J Allergy Clin Immunol*. Published online January 29, 2025. doi:10.1016/j.jaci.2025.01.024
20. Madaudo C, Di Lisi D, Cannatà A, Manfrè F, Vullo C, Santoro M, **Botta C**, Mancuso S, Siragusa S, Galassi AR, Novo G. **"Cardiovascular toxicity induced by TKIs in patients with chronic myeloid leukaemia: Are women and men different?"**. *ESC Heart Fail*. January 9, 2025. doi:10.1002/ehf2.15165
 21. De Novellis D, Derudas D, Vincelli D, Fontana R, Della Pepa R, Palmieri S, Accardi F, Rotondo F, Morelli E, Gigliotta E, Roccotelli D, Marano L, Barone ML, Cetani G, Esposito D, Lazzaro A, Delle Cave G, Serio B, Morini D, Porrazzo M, Urciuoli E, Masucci C, Fanelli F, Rizzo M, Arcamone M, Trastulli F, Rocco S, Leone A, Bianco R, Salvatore F, Idato A, Sicari M, Tosi P, Rascato MG, Di Perna M, Falcone AP, Morello L, Carlisi M, Svanera G, Annunziata M, Frigeri F, Califano C, Carella AM, Marcacci G, Pane F, Risitano AM, Giudice V, **Botta C**, Selleri C. **"Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients."** *Eur J Haematol*. 2025;114(1):105-114. doi:10.1111/ejh.14314
 22. Martino EA, Derudas D, Rossi E, Terlizzi S, Reddiconto G, Stefanoni P, Micozzi J, Mangiacavalli S, Zamagni E, Offidani M, Furlan A, Buda G, Lotti F, Liberatore C, Lazzaro A, Della Pepa R, Bertuglia G, Barbieri E, Conticello C, De Magistris C, De Paoli L, Bongarzone V, Cafro AM, Mele A, Benvenuti P, Cerchione C, **Botta C**, Antonioli E, Sgherza N, Aquino S, Mele G, Barilà G, Palmieri S, Annibali O, Bianco R, Febbo MA, Casaluci GM, Rago A, Fontana R, Farina F, Vigna E, Bruzzese A, Mancuso K, Nappi D, Morè S, Rivolti E, Califano C, Amendola A, Roccotelli D, Lombardo A, Citro A, Uccello G, Zambello R, Maggi A, Neri S, Monachesi M, Gozzetti A, Montefusco V, Brunori M, Cotzia E, Pietrantonio G, Quinto AM, Amico V, Di Renzo N, Coscia M, Galli M, De Stefano V, Petrucci MT, Neri A, Di Raimondo F, Morabito F, Musto P, Gentile M. **"Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials."** *Haematologica*. November 28, 2024. doi:10.3324/haematol.2024.286658
 23. Porrazzo M, Moscato T, Sapienza G, Accardi F, Patti C, Cangialosi C, Costanza C, Bono R, Tringali S, Rotolo C, Gigliotta E, Rizzuto A, Ingrascà MG, Butera G, Di Noto L, Santoro A, Marfia A, **Botta C**, Siragusa S, Martino M, Castagna L. **"Impact of daratumumab/bortezomib/thalidomide and dexamethasone induction therapy on chemo-free stem cell mobilization in transplant eligible newly diagnosed multiple myeloma: a multicentre real-world experience."** *Haematologica*. October 31, 2024. doi:10.3324/haematol.2024.286332
 24. Solimando AG, **Botta C**. **"AURKA targeting: a NEAT approach to**

- halt myeloma.”** Haematologica. 2024 Dec 1. doi: 10.3324/haematol.2024.286085
25. Gigliotta E, Plano F, Corsale G, Corsale AM, Aquilina C, Speciale M, Rizzuto A, Martino EA, Leotta D, Solimando AG, Ria R, Gentile M, Siragusa S & **Botta C**. **“Measurable therapeutic antibody in serum as potential predictive factor of response to anti-CD38 therapy in non-IgG-k myeloma patients.”** *Exp Hematol Oncol*. 2024;13(1):82. Published 2024 Aug 6. doi:10.1186/s40164-024-00547-x
 26. Gulla A, Morelli E, Johnstone M, Turi M, Samur MK, **Botta C**, Cifric S, Folino P, Vinaixa D, Barelo F, Clericuzio C, Favasuli VK, Maisano D, Talluri S, Prabhala RH, Bianchi G, Fulciniti M, Wen K, Kurata K, Liu J, Penailillo J, Bragoni A, Sapino A, Richardson PG, Chauhan D, Carrasco RD, Hideshima T, Munshi NC, Anderson KC. **“Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma.”** *Blood*. 2024 Mar 29;blood.2023022777. doi: 10.1182/blood.2023022777. Epub ahead of print. PMID: 38551812.
 27. Fazio M, Del Fabro V, Parrinello NL, Allegra A, Markovic U, **Botta C**, Accardi F, Vincelli ID, Leotta S, Elia F, Esposito B, Garibaldi B, Sapuppo G, Orofino A, Romano A, Palumbo GA, Di Raimondo F, Conticello C. **“Multiple Myeloma in 2023 Ways: From Trials to Real Life.”** *Curr Oncol*. 2023 Nov 3;30(11):9710-9733. doi: 10.3390/curroncol30110705.
 28. **Botta C**, Perez C, Larrayoz M, Puig N, Cedena MT, Termini R, Goicoechea I, Rodriguez S, Zabaleta A, Lopez A, Sarvide S, Blanco L, Papetti DM, Nobile MS, Besozzi D, Gentile M, Correale P, Siragusa S, Oriol A, González-Garcia ME, Sureda A, de Arriba F, Rios Tamayo R, Moraleta JM, Gironella M, Hernandez MT, Bargay J, Palomera L, Pérez-Montaña A, Goldschmidt H, Avet-Loiseau H, Roccaro A, Orfao A, Martinez-Lopez J, Rosiñol L, Lahuerta JJ, Blade J, Mateos MV, San-Miguel JF, Martinez Climent JA, Paiva B; Programa Para el Estudio de la Terapéutica en Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) cooperative group; iMMunocell study group. **“Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance.”** *Nat Commun*. 2023 Sep 20;14(1):5825. doi: 10.1038/s41467-023-41562-6.
 29. Battaglia AM, Sacco A, Aversa I, Santamaria G, Palmieri C, **Botta C**, De Stefano R, Bitetto M, Petriaggi L, Giorgio E, Faniello CM, Costanzo F, Biamonte F. **“Iron-mediated oxidative stress induces PD-L1 expression via activation of c-Myc in lung adenocarcinoma.”** *Front Cell Dev Biol*. 2023 Jun 12;11:1208485. doi: 10.3389/fcell.2023.1208485.
 30. Rizzuto A, Pirrera A, Gigliotta E, Mancuso S, Vullo C, Camarda GM, Rotolo C, Roppolo A, Spoto C, Gentile M, **Botta C***, Siragusa S*. **“Molecular-Biology-Driven Frontline Treatment for Chronic Lymphocytic Leukemia: A Network Meta-Analysis of**

31. Plano F, Gigliotta E, Corsale AM, Azgomi MS, Santonocito C, Ingrassi M, Di Carlo L, Augello AE, Speciale M, Vullo C, Rotolo C, Camarda GM, Caccamo N, Meraviglia S, Dieli F, Siragusa S, **Botta C**. **“Ferritin Metabolism Reflects Multiple Myeloma Microenvironment and Predicts Patient Outcome.”** Int J Mol Sci. 2023 May 16;24(10):8852. doi: 10.3390/ijms24108852
32. Mohammadnezhad L, Shekarkar Azgomi M, La Manna MP, Guggino G, **Botta C**, Dieli F, Caccamo N. **“B-Cell Receptor Signaling Is Thought to Be a Bridge between Primary Sjogren Syndrome and Diffuse Large B-Cell Lymphoma.”** Int J Mol Sci. 2023 May 7;24(9):8385. doi: 10.3390/ijms24098385.
33. Larrayoz M, Garcia-Barchino MJ, Celay J, Etxebeste A, Jimenez M, Perez C, Ordoñez R, Cobaleda C, **Botta C**, Fresquet V, Roa S, Goicoechea I, Maia C, Lasaga M, Chesi M, Bergsagel PL, Larrayoz MJ, Calasanz MJ, Campos-Sanchez E, Martinez-Cano J, Panizo C, Rodriguez-Otero P, Vicent S, Roncador G, Gonzalez P, Takahashi S, Katz SG, Walensky LD, Ruppert SM, Lasater EA, Amann M, Lozano T, Llopiz D, Sarobe P, Lasarte JJ, Planell N, Gomez-Cabrero D, Kudryashova O, Kurilovich A, Revuelta MV, Cerchietti L, Agirre X, San Miguel J, Paiva B, Prosper F, Martinez-Climent JA. **“Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma.”** Nat Med. 2023 Mar;29(3):632-645. doi: 10.1038/s41591-022-02178-3.
34. Plano F, Corsale AM, Gigliotta E, Camarda G, Vullo C, Di Simone M, Shekarkar Azgomi M, Speciale M, Carlisi M, Caccamo N, Dieli F, Meraviglia S, Siragusa S, **Botta C**. **“Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again.”** Hematol Rep. 2023 Jan 9;15(1):23-49. doi: 10.3390/hematolrep15010004.
35. Fameli A, Nardone V, Shekarkar Azgomi M, Bianco G, Gandolfo C, Oliva BM, Monoriti M, Saladino RE, Falzea A, Romeo C, Calandruccio ND, Azzarello D, Giannicola R, Pirtoli L, Giordano A, Tassone P, Tagliaferri P, Cusi MG, Mutti L, **Botta C**, Correale P. **“PD-1/PD-L1 immune-checkpoint blockade induces immune effector cell modulation in metastatic non-small cell lung cancer patients: A single-cell flow cytometry approach.”** Front Oncol. 2022 Sep 14;12:911579. doi: 10.3389/fonc.2022.911579.
36. Termini R, Zihala D, Terpos E, Pérez-Montaña A, Jelinek T, Raab M, Weinhold N, Mai EK, Grab AL, Corre J, Vergez F, Sacco A, Chiarini M, Giustini V, Tucci A, Rodríguez S, Moreno C, Perez C, Maia C, Martin-Sanchez E, Guerrero C, **Botta C**, Garcés JJ, Lopez A, Tamariz-Amador LE, Prósper F, Bargay J, Cabezero ME, Ocio EM, Hájek R, Martinez-Lopez J, Solano F, Iglesias R, Paiva A,

- Geraldes C, Matos Silva H, Gomez C, De Arriba F, Ludwig H, Garcia-Guiñon A, Casanova M, Alegre A, Cabañas V, Sirvent M, Oriol A, De la Rubia J, Hernández-Rivas JÁ, Palomera L, Sarasa M, Rios P, Puig N, Mateos MV, Flores-Montero J, Orfao A, Goldschmidt H, Avet-Loiseau H, Roccaro AM, San-Miguel JF, Paiva B. **“Circulating tumor and immune cells for minimally invasive risk stratification of smoldering multiple myeloma.”** Clin Cancer Res. 2022 Sep 8;CCR-22-1594. doi: 10.1158/1078-0432.CCR-22-1594.
37. Morabito F, Zamagni E, Conticello C, Pavone V, Palmieri S, Bringhen S, Galli M, Mangiacavalli S, Derudas D, Rossi E, Ria R, Catalano L, Tacchetti P, Mele G, Vincelli ID, Martino EA, Vigna E, Bruzzese A, Mendicino F, **Botta C**, Mele A, Pantani L, Rocchi S, Garibaldi B, Cascavilla N, Ballanti S, Tripepi G, Frigeri F, Falcone AP, Cangialosi C, Reddicono G, Farina G, Barone M, Rizzello I, Iaccino E, Mimmi S, Curci P, Gamberi B, Musto P, De Stefano V, Musso M, Petrucci MT, Offidani M, Di Raimondo F, Boccadoro M, Cavo M, Neri A, Gentile M. **“Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials.”** Front Oncol. 2022 Jul 18;12:890376. doi: 10.3389/fonc.2022.890376
 38. **Botta C**, Gigliotta E, Paiva B, Anselmo R, Santoro M, Otero PR, Carlisi M, Conticello C, Romano A, Solimando AG, Cerchione C, Vià MD, Bolli N, Correale P, Di Raimondo F, Gentile M, San Miguel J, Siragusa S. **“Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant.”** Hematol Oncol. 2022 Jul 6. doi: 10.1002/hon.3041
 39. Martino EA, Conticello C, Zamagni E, Pavone V, Palmieri S, Musso M, Tacchetti P, Mele A, Catalano L, Vigna E, Bruzzese A, Mendicino F, **Botta C**, Vincelli ID, Farina G, Barone M, Cangialosi C, Mancuso K, Rizziello I, Rocchi S, Falcone AP, Mele G, Reddicono G, Garibaldi B, Iaccino E, Tripepi G, Gamberi B, Di Raimondo F, Musto P, Neri A, Cavo M, Morabito F, Gentile M. **“Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials.”** Hematol Oncol. 2022 May 31. doi: 10.1002/hon.3035.
 40. Bruzzese A, Derudas D, Galli M, Martino EA, Rocco S, Conticello C, Califano C, Giuliani N, Mangiacavalli S, Farina G, Lombardo A, Brunori M, Rossi E, Antonioli E, Ria R, Zambello R, Di Renzo N, Mele G, Marcacci G, Pietrantuono G, Palumbo G, Cascavilla N, Cerchione C, Belotti A, Criscuolo C, Uccello G, Curci P, Vigna E, Mendicino F, Iaccino E, Mimmi S, **Botta C**, Vincelli D, Sgherza N, Bonalumi A, Cupelli L, Stocchi R, Martino M, Ballanti S, Gangemi D,

- Gagliardi A, Gamberi B, Pompa A, Tripepi G, Frigeri F, Consoli U, Brighen S, Zamagni E, Patriarca F, De Stefano V, Di Raimondo F, Palmieri S, Petrucci MT, Offidani M, Musto P, Boccadoro M, Cavo M, Neri A, Morabito F, Gentile M. ***“Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials.”*** Hematol Oncol. 2022 May 24.
41. Romano A, Parrinello NL, Barchitta M, Manuele R, Puglisi F, Maugeri A, Barbato A, Triolo AM, Giallongo C, Tibullo D, La Ferla L, **Botta C**, Siragusa S, Iacobello C, Montineri A, Volti GL, Agodi A, Palumbo GA, Di Raimondo F. ***“In-vitro NET-osis induced by COVID-19 sera is associated to severe clinical course in not vaccinated patients and immune-dysregulation in breakthrough infection.”*** Sci Rep. 2022 May 4
 42. Guerrero C, Puig N, Cedena MT, Goicoechea I, Perez C, Garces JJ, **Botta C**, Calasanz MJ, Gutierrez NC, Martin-Ramos ML, Oriol A, Rios R, Hernandez MT, Martinez-Martinez R, Bargay J, de Arriba F, Palomera L, Gonzalez-Rodriguez AP, Mosquera-Orgueira A, Gonzalez-Perez MS, Martinez-Lopez J, Lahuerta JJ, Rosiñol L, Blade J, Mateos MV, San Miguel JF, Paiva B. ***“A machine learning model based on tumor and immune biomarkers to predict undetectable MRD and survival outcomes in multiple myeloma.”*** Clin Cancer Res. 2022 Jan 21
 43. Rodriguez S, Celay J, Goicoechea I, Jimenez C, **Botta C**, Garcia-Barchino MJ, Garces JJ, Larrayoz M, Santos S, Alignani D, Vilas-Zornoza A, Perez C, Garate S, Sarvide S, Lopez A, Reinhardt HC, Carrasco YR, Sanchez-Garcia I, Larrayoz MJ, Calasanz MJ, Panizo C, Prosper F, Lamo-Espinosa JM, Motta M, Tucci A, Sacco A, Gentile M, Duarte S, Vitoria H, Geraldine C, Paiva A, Puig N, Garcia-Sanz R, Rocco AM, Fuerte G, San Miguel JF, Martinez-Climent JA, Paiva B. ***“Preneoplastic somatic mutations including MYD88^{L265P} in lymphoplasmacytic lymphoma.”*** Sci Adv. 2022 Jan 21
 44. Tamariz-Amador LE, Battaglia AM, Maia C, Zherniakova A, Guerrero C, Zabaleta A, Burgos L, **Botta C**, Fortuño MA, Grande C, Manubens A, Arguiñano JM, Gomez C, Perez-Persona E, Olazabal I, Oñativia I, Panizo C, Prosper F, San-Miguel JF, Rodriguez-Otero P, Martín-Sánchez E, Paiva B; The Asociación Vasco-Navarra de Hematología y Hemoterapia (ASOVASNA) Cooperative Group. ***“Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies.”*** Blood Cancer J. 2021 Dec 14;
 45. Sant'Antonio E, Borsani O, Camerini C, **Botta C**, Santoro M, Allegra A, Siragusa S. ***“Philadelphia chromosome-negative myeloproliferative neoplasms in younger adults: A critical discussion of unmet medical needs, with a focus on***

pregnancy." Blood Rev. 2021 Oct 29:

46. Morabito F, Zamagni E, Conticello C, Pavone V, Palmieri S, Brighen S, Galli M, Mangiacavalli S, Derudas D, Rossi E, Ria R, Catalano L, Tacchetti P, Mele G, Donatella Vincelli I, Antonia Martino E, Vigna E, **Botta C**, Bruzzese A, Mele A, Pantani L, Rocchi S, Garibaldi B, Cascavilla N, Ballanti S, Tripepi G, Frigeri F, Pia Falcone A, Cangialosi C, Reddicono G, Farina G, Barone M, Rizzello I, Musto P, De Stefano V, Musso M, Teresa Petrucci M, Offidani M, Neri A, Di Renzo N, Di Raimondo F, Boccadoro M, Cavo M, Gentile M. **"Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients"**. Eur J Haematol. 2021 Oct 30.
47. **Botta C**, Maia CDS, Garcés JJ, Termini R, Perez C, Manrique I, Burgos L, Zabaleta A, Alignani D, Sarvide S, Merino J, Puig N, Cedena MT, Rossi M, Tassone P, Gentile M, Correale P, Borrello I, Terpos E, Jelinek T, Paiva A, Rocco AM, Goldschmidt H, Avet-Loiseau H, Rosinol Dachs L, Mateos MV, Martinez-Lopez J, Lahuerta JJ, Bladé J, San-Miguel JF, Paiva B. **"FlowCT for the analysis of large immunophenotypic datasets and biomarker discovery in cancer immunology"** Blood Adv. 2021 Sep 29
48. Mendicino F, Santoro C, Martino E, **Botta C**, Baldacci E, Ferretti A, Muto B, Lucia E, Caracciolo D, Vigna E, Morelli M, Gentile M. **"Eltrombopag treatment for severe immune thrombocytopenia during pregnancy: a case report"**. Blood Coagul Fibrinolysis. 2021 Oct 1
49. **Botta C**, Mendicino F, Martino EA, Vigna E, Ronchetti D, Correale P, Morabito F, Neri A, Gentile M. **"Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities"**. Cancers (Basel). 2021 Jun 28;13(13):3213.
50. **Botta C**, Agostino RM, Dattola V, Cianci V, Calandruccio ND, Bianco G, Mafodda A, Maisano R, Iuliano E, Orizzonte G, Mazzacuva D, Falzea AC, Saladino RE, Giannicola R, Restifo G, Aguglia U, Caraglia M, Correale P. **"Myositis/Myasthenia after Pembrolizumab in a Bladder Cancer Patient with an Autoimmunity-Associated HLA: Immune-Biological Evaluation and Case Report"** Int J Mol Sci. 2021 Jun 10;22(12):6246.
51. Vicario N, Spitale FM, Tibullo D, Giallongo C, Amorini AM, Scandura G, Spoto G, Saab MW, D'Aprile S, Alberghina C, Mangione R, Bernstock JD, **Botta C**, Gulisano M, Buratti E, Leanza G, Zorec R, Vecchio M, Di Rosa M, Li Volti G, Lazzarino G, Parenti R, Gulino R. **"Clobetasol promotes neuromuscular plasticity in mice after motoneuronal loss via sonic hedgehog signaling, immunomodulation and metabolic rebalancing"**. Cell Death Dis. 2021 Jun 16;12(7):625.

52. Martín-Sánchez E, Garcés JJ, Maia C, Inogés S, López-Díaz de Cerio A, Carmona-Torre F, Marin-Oto M, Alegre F, Molano E, Fernandez-Alonso M, Perez C, **Botta C**, Zabaleta A, Alcaide AB, Landecho MF, Rua M, Pérez-Warnisher T, Blanco L, Sarvide S, Vilas-Zornoza A, Alignani D, Moreno C, Pineda I, Sogbe M, Argemi J, Paiva B, Yuste JR. **"Immunological Biomarkers of Fatal COVID-19: A Study of 868 Patients"**. Front Immunol. 2021 May
53. **Botta, C.**, Martino, E. A., Conticello, C., Mendicino, F., Vigna, E., Romano, A., Palumbo GA, Cerchione C, Martinelli G, Morabito F, Di Raimondo F & Gentile, M. (2021). **"Treatment of lenalidomide exposed or refractory multiple myeloma: Network meta-analysis of lenalidomide-sparing regimens"** Frontiers in Oncology, 11, 1073, 2021.
54. Gulla A, Morelli E, Samur MK, **Botta C**, Hideshima T, Bianchi G, Fulcinitti M, Malvestiti S, Prabhala RH, Talluri S et al: **"Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation."** Blood Cancer Discovery 2021: bloodcandisc.BCD-21-0047-A.2021
55. Biamonte F*, **Botta C***, Mazzitelli M, Rotundo S, Trecarichi EM, Foti D, Torti C, Viglietto G, Torella D, Costanzo F. **"Combined lymphocyte/monocyte count, D-dimer and iron status predict COVID-19 course and outcome in a long-term care facility"**. J Transl Med 19, 79 (2021).
***Equally contributed to this work**
56. Caracciolo, D., C. Riillo, A. Ballerini, G. Gaipa, L. Lhermitte, M. Rossi, **C. Botta**, E. Duroyon, K. Grillone, M. E. Gallo Cantafio, C. Buracchi, G. Alampi, A. Gulino, B. Belmonte, F. Conforti, G. Golino, G. Juli, E. Altomare, N. Polerà, F. Scionti, M. Arbitrio, M. Iannone, M. Martino, P. Correale, G. Talarico, A. Ghelli Luserna di Rorà, A. Ferrari, D. Concolino, S. Sestito, L. Pensabene, A. Giordano, M. Hildinger, M. T. Di Martino, G. Martinelli, C. Tripodo, V. Asnafi, A. Biondi, P. Tagliaferri and P. Tassone (2021). **"Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia."** Journal for ImmunoTherapy of Cancer 9(2): e002026
57. Morabito F, Tripepi G, Del Poeta G, Mauro FR, Reda G, Sportoletti P, Laurenti L, Coscia M, Herishanu Y, Varettoni M, Murru R, Chiarenza A, Visentin A, Condoluci A, Moia R, Pietrasanta D, Loseto G, Consoli U, Scortechini I, Rossi FM, Zucchetto A, Vigna E, Martino EA, Mendicino F, **Botta C**, Caracciolo D, Cassin R, D'Arrigo G, Galimberti S, Rago A, Angeletti I, Biagi A, Del Giudice I, Bomben R, Neri A, Fronza G, Cutrona G, Rossi D, Di Raimondo F, Cuneo A, Gaidano G, Polliack A, Trentin L, Foà R, Ferrarini M, Gattei V,

Gentile M. ***“Assessment of the 4-factor score: retrospective analysis of 586 cll patients receiving ibrutinib. A campus cll study.”*** Am J Hematol. 2021 Feb 13.

58. Sacco A, Battaglia AM, **Botta C**, Aversa I, Mancuso S, Costanzo F, Biamonte F. ***“Iron Metabolism in the Tumor Microenvironment- Implications for Anti-Cancer Immune Response.”*** Cells. 2021 Feb 2;10(2):303.

59. **Botta C***, Indrieri A, Garofalo E, Biamonte F, Bruni A, Pasqua P, Cesario F, Costanzo FS, Longhini F and Mendicino F*. ***“COVID-19: high-JAKing of the inflammatory “flight” by ruxolitinib to avoid the cytokine storm”*** Frontiers in Oncology 2020, in press
****Equally contributed to this work and should be considered as co-first and co-last authors***

60. Rossi M, Altomare E, **Botta C**, Gallo Cantafio ME, Sarvide S, Caracciolo D, Riillo C, Gaspari M, Taverna D, Conforti F, Critelli P, Bertucci B, Iannone M, Polera N, Scumaci F, Arbitrio M, Amodio N, Di Martino MT, Paiva B, Tagliaferri P and Tassone P. ***“miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma”***. Leukemia, in press

61. **Botta C**, Caruso N, Bossio S, Storino F, Console G, Martino M, Mendicino F, Lucia E, Morelli R, Correale P, Morabito F, Gentile M and Vigna E. ***“Long-Term Remission Achieved by Ponatinib and Donor Lymphocytes infusion in a Ph+ Acute Lymphoblastic leukemia patient in molecular relapse after Allogeneic Stem Cell Transplant and Dasatinib: A Case Report”***, Front Oncol. 2020 May 15

62. Perez C*, **Botta C***, Zabaleta A, Puig N, Cedena MT, Goicoechea I, Alameda D, San-José Enériz E, Merino J, Rodríguez-Otero P, Maia CADS, Aligned D, Maiso P, Manrique I, Lara-Astiaso D, Vilas-Zornoza A, Sarvide S, Riillo C, Rossi M, Rosiñol L, Oriol A, Blanchard MJ, Rios R, Sureda A, Martín Sánchez J, Martínez R, Bargay J, de la Rubia J, Hernandez Garcia MT, Martínez-López J, Orfao A, Agirre X, Prosper F, Mateos MV, Lahuerta JJ, Bladé J, San Miguel J, Paiva B. ***“Immunogenomic identification and characterization of granulocytic myeloid derived suppressor cells in multiple myeloma.”*** Blood. 2020 Apr 23.
****Equally contributed to this work***

63. Maia CADS, Puig N, Cedena MT, Goicoechea I, Valdés-Mas R, Vazquez I, Chillon MC, Aguirre P, Sarvide S, Gracia-Aznárez FJ, Alkorta-Aranburu G, Calasanz MJ, Garcia-Sanz R, González M, Gutierrez N, Martinez-Lopez J, Perez JJ, Merino J, Moreno C,

- Burgos L, Alignani D, **Botta C**, Prosper F, Matarraz S, Orfao A, Oriol A, Teruel AI, de Paz R, de Arriba F, Hernandez Garcia MT, Palomera L, Martinez R, Rosiñol L, Mateos MV, Lahuerta JJ, Bladé J, San Miguel J, Paiva B. **"Biological and clinical significance of dysplastic hematopoiesis in patients with newly-diagnosed multiple myeloma."** Blood. 2020 Apr 16
64. Gentile M, Morabito F, Del Poeta G, Mauro FR, Reda G, Sportoletti P, Laurenti L, Coscia M, Herishanu Y, Recchia AG, Varettoni M, Murru R, Chiarenza A, Condoluci A, Moia R, Pietrasanta D, Loseto G, Consoli U, Scortechini I, Rossi FM, Zucchetto A, Fraticelli V, Vigna E, **Botta C**, Tripepi G, Arrigo G, Rago A, Angeletti I, Biagi A, Del Giudice I, Bomben R, Rigolin GM, Rossi D, Di Raimondo F, Gaidano G, Polliack A, Cuneo A, Foà R, Gattei V. **"Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study."** Leukemia. 2020 Apr 14.
65. Gentile M, Specchia G, Derudas D, Galli M, **Botta C**, Rocco S, Conticello C, Califano C, Giuliani N, Mangiacavalli S, Attingenti E, Lombardo A, Brunori M, Rossi E, Antonioli E, Ria R, Zambello R, Di Renzo N, Mele G, Marcacci G, Musto P, Capalbo S, Cascavilla N, Cerchione C, Belotti A, Criscuolo C, Uccello G, Curci P, Vigna E, Fraticelli V, Vincelli D, Bonalumi A, Siniscalchi A, Stocchi R, Martino M, Ballanti S, Gangemi D, Gagliardi A, Gamberi B, Pompa A, Recchia AG, Tripepi G, Pitino A, Frigeri F, Consoli U, Brighen S, Zamagni E, Patriarca F, De Stefano V, Di Raimondo F, Palmieri S, Petrucci MT, Offidani M, Boccadoro M, Cavo M, Morabito F. **"Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials."** Haematologica. 2020 Feb 27
66. Limongi T, Dattola E, **Botta C**, Coluccio ML, Candeloro P, Cucè M, Scopacasa B, Gallo Cantafio ME, Critello CD, Pullano SA, Fiorillo AS, Tagliaferri P, Tassone P, Lamanna E, Di Fabrizio E, Perozziello G. **"Influence of the Fabrication Accuracy of Hot-Embossed PCL Scaffolds on Cell Growths."** Front Bioeng Biotechnol. 2020 Feb 14
67. Correale P, Saladino RE, Nardone V, Giannicola R, Agostino R, Pirtoli L, Caraglia M, **Botta C**, Tagliaferri P. **"Could PD-1/PDL1 immune checkpoints be linked to HLA signature?"** Immunotherapy. 2019 Dec
68. Nardone V, Tini P, Pastina P, **Botta C**, Reginelli A, Carbone SF, Giannicola R, Calabrese G, Tebala C, Guida C, Giudice A, Barbieri V, Tassone P, Tagliaferri P, Cappabianca S, Capasso R, Luce A, Caraglia M, Mazzei MA, Pirtoli L, Correale P **"Radiomics predicts survival of patients with advanced non-small cell lung cancer undergoing PD-1 blockade using Nivolumab"**. Oncology Letters

0.0 (1899)

69. Morabito F, Recchia AG, Vigna E, **Botta C**, Skafi M, Abu-Rayyan M, Atrash M, Galimberti S, Morabito L, Al-Janazreh H, Martino M, Cutrona G, Gentile M. **"An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma."** Expert Opin Pharmacother. 2019 Nov
70. Caraglia M, Correale P, Giannicola R, Staropoli N, **Botta C**, Pastina P, Nesci A, Caporlingua N, Francini E, Ridolfi L, Mini E, Roviello G, Ciliberto D, Agostino RM, Strangio A, Azzarello D, Nardone V, Falzea A, Cappabianca S, Bocchetti M, D'Arrigo G, Tripepi G, Tassone P, Addeo R, Giordano A, Pirtoli L, Francini G, Tagliaferri P. **"GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up."** Front Oncol. 2019 Nov
71. Garcés JJ, Simicek M, Vicari M, Brozova L, Burgos L, Bezdekova R, Alignani D, Calasanz MJ, Growkova K, Goicoechea I, Agirre X, Pour L, Prosper F, Rios R, Martinez-Lopez J, Millacoy P, Palomera L, Del Orbe R, Perez-Montaña A, Garate S, Blanco L, Lasa M, Maiso P, Flores-Montero J, Sanoja-Flores L, Chyra Z, Vdovin A, Sevcikova T, Jelinek T, **Botta C**, El Omri H, Keats J, Orfao A, Hajek R, San-Miguel JF, Paiva B. **"Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination."** Leukemia. 2019 Oct 8.
72. Giannicola R, D'Arrigo G, **Botta C**, Agostino R, Del Medico P, Falzea AC, Barbieri V, Staropoli N, Del Giudice T, Pastina P, Nardone V, Monoriti M, Calabrese G, Tripepi G, Pirtoli L, Tassone P, Tagliaferri P, Correale P. **"Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab"** Mol Clin Oncol. 2019 Jul
73. Cucè M, Gallo Cantafio ME, Siciliano MA, Riillo C, Caracciolo D, Scionti F, Staropoli N, Zuccalà V, Maltese L, Di Vito A, Grillone K, Barbieri V, Arbitrio M, Di Martino MT, Rossi M, Amodio N, Tagliaferri P, Tassone P and **Botta C**. **"Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma"** J Hematol Oncol. 2019 Mar
74. Amodio N, Gallo Cantafio ME, **Botta C**, Agosti V, Federico C, Caracciolo D, Ronchetti D, Rossi M, Driessen C, Neri A, Tagliaferri P, Tassone P. **"Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma."** Cancers (Basel). 2019 Feb 18
75. Caracciolo D, Di Martino MT, Amodio N, Morelli E, Montesano M,

- Botta C**, Scionti F, Talarico D, Altomare E, Gallo Cantafio ME, Zuccalà V, Maltese L, Todoerti K, Rossi M, Arbitrio M, Neri A, Tagliaferri P, Tassone P. **"miR-22 suppresses DNA ligase III addiction in multiple myeloma"**. Leukemia. 2019 Feb
76. D'Agostino S, Lanzillotta D, Varano M, **Botta C**, Baldrini A, Bilotta A, Scalise S, Dattilo V, Amato R, Gaudio E, Paduano F, Palmieri C, Iuliano R, Perrotti N, Indiveri C, Fusco A, Gaspari M, Trapasso F. **"The receptor protein tyrosine phosphatase PTPRJ negatively modulates the CD98hc oncoprotein in lung cancer cells."** Oncotarget. 2018 May 4
 77. Correale P, **Botta C**, Staropoli N, Nardone V, Pastina P, Ulivieri C, Gandolfo C, Baldari TC, Lazzi S, Ciliberto D, Giannicola R, Fioravanti A, Giordano A, Zappavigna S, Caraglia M, Tassone P, Pirtoli L, Cusi MG, Tagliaferri P. **"Systemic inflammatory status predict the outcome of k-RAS WT metastatic colorectal cancer patients receiving the thymidylate synthase poly-epitope-peptide anticancer vaccine."** Oncotarget. 2018 Apr 17
 78. Rossi M, **Botta C**, Arbitrio M, Grembiale RD, Tagliaferri P, Tassone P. **"Mouse models of multiple myeloma: technologic platforms and perspectives."** Oncotarget. 2018 Apr 13
 79. Ciliberto D, Staropoli N, Caglioti F, Chiellino S, Ierardi A, Ingargiola R, **Botta C**, Arbitrio M, Correale P, Tassone P, Tagliaferri P. **"The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis."** Crit Rev Oncol Hematol. 2018 May
 80. **Botta C**, Cucè M, Pitari MR, Caracciolo D, Gullà A, Morelli E, Riillo C, Biamonte L, Cantafio MEG, Prabhala R, Mignogna C, Di Vito A, Altomare E, Amodio N, Di Martino MT, Correale P, Rossi M, Giordano A, Munshi NC, Tagliaferri P, Tassone P. **"MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells"**. Leukemia. 2017 Nov
 81. Pastina P, Nardone V, **Botta C**, Croci S, Tini P, Battaglia G, Ricci V, Cusi MG, Gandolfo C, Misso G, Zappavigna S, Caraglia M, Giordano A, Aldinucci A, Tassone P, Tagliaferri P, Pirtoli L and Correale P **"Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBv)"**. Oncotarget. 2017
 82. Pastina P, Nardone V, Croci S, Battaglia G, Vanni F, Bellan C, Barbarino M, Ricci V, Costantini S, Capone F, **Botta C**, Zarone M, Misso G, Boccellino M, Caraglia M, Giordano A, Paladini P, Tassone P, Tagliaferri P, Cusi M, Pirtoli L, and Correale P. **"Anti-**

- cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients” Journal Of Thoracic Disease, 2017.
83. **Botta C**, Cucè M, Caracciolo D, Fiorillo L, Tagliaferri P, Tassone P. **“Immunomodulatory activity of microRNAs: potential implications for multiple myeloma treatment.”** Curr Cancer Drug Targets. 2017 Mar
 84. **Botta C**, Ciliberto D, Rossi M, Staropoli N, Cucè M, Galeano T, Tagliaferri P, Tassone P. **“Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients.”** Blood Adv. 2017 Feb
 85. **Botta C**, Di Martino MT, Ciliberto D, Cucè M, Correale P, Rossi M, Tagliaferri P, Tassone P. **“A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival.”** Blood Cancer J. 2016 Dec
 86. Staropoli N, Ciliberto D, Chiellino S, Caglioti F, Giudice TD, Gualtieri S, Salvino A, Strangio A, **Botta C**, Pignata S, Tassone P, Tagliaferri P. **“Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation.”** Oncotarget. 2016 Dec
 87. Correale P, **Botta C**, Ciliberto D, Pastina P, Ingargiola R, Zappavigna S, Tassone P, Pirtoli L, Caraglia M and Tagliaferri P. **“Immunotherapy of colorectal cancer: new perspectives after a long path”** Immunotherapy 2016 Nov
 88. Nardone V, **Botta C**, Martino E, Ambrosio M, Carfagno T, Tini P, Semeraro L, Misso G, Grimaldi A, Boccellino M, Facchini G, Berretta M, Vischi G, Rocca B, Barone A, Tassone P, Tagliaferri P, Del Vecchio M, Pirtoli L, and Correale P. **“Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse”** Cancer Biol Ther. 2016 Nov
 89. Agapito G*, **Botta C***, Guzzi PH, Arbitrio M, Di Martino MT, Tassone P, Tagliaferri P and Cannataro M. **“OSAnalyzer: A Bioinformatics Tool for the Analysis of Gene Polymorphisms Enriched with Clinical Outcomes.”** Microarrays (Basel). 2016 Sep 23
***equally contributed**
 90. **Botta C**, Misso G, Martino EC, Pirtoli L, Cusi MG, Tassone P, Tagliaferri P, Caraglia M, and Correale P. **“The route to solve the interplay between inflammation, angiogenesis and anti-cancer immune response”** Cell Death Dis. 2016 Jul 21
 91. Martino EC, Misso G, Pastina P, Costantini S, Vanni F, Gandolfo C,

- Botta C**, Capone F, Lombardi A, Pirtoli L, Tassone P, Ulivieri C, Tagliaferri P, Cusi MG, Caraglia M and Correale P **“Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients”** Cell Death Discov. 2016 *In press*
92. Gallo Cantafio ME, Nielsen BS, Mignogna C, Arbitrio M, **Botta C**, Frandsen NM, Rolfo C, Tagliaferri P, Tassone P, Di Martino MT. **“Pharmacokinetics and Pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in Mice and Non-human Primates.”** Mol Ther Nucleic Acids. 2016 Jun 21
 93. Mignogna C, Staropoli N, **Botta C**, De Marco C, Rizzuto A, Morelli M, Di Cello A, Franco R, Camastra C, Presta I, Malara N, Salvino A, Tassone P, Tagliaferri P, Barni T, Donato G, Di Vito A. **“Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients.”** J Ovarian Res. 2016 May 21
 94. Correale P, **Botta C**, Martino EC, Ulivieri C, Battaglia G, Carfagno T, MG, Fioravanti A, Guidelli GM, Cheleschi S, Gandolfo C, Carbone F, Baldari TC, Tassone P, Tagliaferri P, Pirtoli L, Cusi MG. **“Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patients.”** Oncoimmunology. 2015 Dec
 95. Ciliberto D, Staropoli N, Chiellino S, **Botta C**, Tassone P, Tagliaferri P. **“Systematic review and meta-analysis on targeted therapy in advanced pancreatic cancer”**. Pancreatology. 2016 Mar-Apr
 96. Arbitrio M, Di Martino MT, Barbieri V, Agapito G, Guzzi PH, **Botta C**, Iuliano E, Scionti F, Altomare E, Codispoti S, Conforti S, Cannataro M, Tassone P, Tagliaferri P. **“Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis.”** Cancer Chemother Pharmacol. 2016 Jan
 97. Gullà A, Di Martino MT, Gallo Cantafio ME, Morelli E, Amodio N, **Botta C**, Pitari MR, Lio SG, Britti D, Stamato MA, Hideshima T, Munshi NC, Anderson KC, Tagliaferri P, Tassone P. **“A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells.”** Clin Cancer Res. 2016 Mar 1
 98. Pitari MR, Rossi M, Amodio N, **Botta C**, Morelli E, Federico C, Gullà A, Caracciolo D, Di Martino MT, Arbitrio M, Giordano A, Tagliaferri P, Tassone P. **“Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts.”** Oncotarget. 2015 Sep 29

99. Ciliberto D, Staropoli N, Caglioti F, Gualtieri S, Fiorillo L, Chiellino S, De Angelis AM, Mendicino F, **Botta C**, Caraglia M, Tassone P, Tagliaferri P. **"A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate?"** Cancer Biol Ther. 2015
100. Cusi MG*, **Botta C***, Pastina P, Rossetti MG, Dreassi E, Guidelli GM, Fioravanti A, Martino EC, Gandolfo C, Pagliuchi M, Basile A, Carbone SF, Ricci V, Micheli L, Tassone P, Tagliaferri P, Pirtoli L, Correale P. **"Phase I trial of thymidylate synthase poly-epitope peptide (TSPP) vaccine in advanced cancer patients. Cancer Immunol Immunother."** 2015 Sep. **equally contributed*
101. Morelli E, Leone E, Cantafio ME, Di Martino MT, Amodio N, Biamonte L, Gullà A, Foresta U, Pitari MR, **Botta C**, Rossi M, Neri A, Munshi NC, Anderson KC, Tagliaferri P, Tassone P. **"Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo"**. Leukemia. 2015 Nov
102. Amodio N, Rossi M, Raimondi L, Pitari MR, **Botta C**, Tagliaferri P, Tassone P. **"miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies."** Oncotarget. 2015 May 30
103. **Botta C**, Gullà A, Correale P, Tagliaferri P, Tassone P. **"Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities."** Front Oncol. 2014 Dec 8
104. Leotta M, Biamonte L, Raimondi L, Ronchetti D, Martino MT, **Botta C**, Leone E, Pitari MR, Neri A, Giordano A, Tagliaferri P, Tassone P, Amodio N. **"A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells in vitro."** J Cell Physiol. 2014 May 13.
105. Staropoli N, Ciliberto D, **Botta C**, Fiorillo L, Grimaldi A, Lama S, Caraglia M, Salvino A, Tassone P, Tagliaferri P. **"Pegylated liposomal doxorubicin in the management of ovarian cancer: a systematic review and metaanalysis of randomized trials."** Cancer Biol Ther. 2014 Jun 1;15(6):707-20.
106. Correale P, **Botta C**, Rotundo MS, Guglielmo A, Conca R, Licchetta A, Pastina P, Bestoso E, Ciliberto D, Cusi MG, Fioravanti A, Guidelli GM, Bianco MT, Misso G, Martino E, Caraglia M, Tassone P, Mini

- E, Mantovani G, Ridolfi R, Pirtoli L, Tagliaferri P. **"Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: the GOLFIG-2 multicentric open-label randomized phase III trial."** J Immunother. 2014 Jan;37(1):26-35.
107. N Staropoli, **C Botta**, D Ciliberto, L Fiorillo, AM De Angelis, C Viscomi, S Gualtieri, A Salvino, P Tassone, P Tagliaferri **"Target Therapy in Platinum-Refractory/Resistant Ovarian Cancer: From Preclinical Findings to Current Clinical Practice"** Journal of Cancer Therapy. 2013; 4(5)
 108. **Botta C**, Barbieri V, Ciliberto D, Rossi A, Rocco D, Addeo R, Staropoli N, Pastina P, Marvaso G, Martellucci I, Guglielmo A, Pirtoli L, Sperlongano P, Gridelli C, Caraglia M, Tassone P, Tagliaferri P, Correale P. **"Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients."** Cancer Biol Ther. 2013 Jun;14(6):469-75.
 109. Rossi M, **Botta C**, Correale P, Tassone P, Tagliaferri P. **"Immunologic microenvironment and personalized treatment in multiple myeloma."** Expert Opin Biol Ther. 2013 Jun;13 Suppl 1:S83-93.
 110. Staropoli N, Ciliberto D, **Botta C**, Fiorillo L, Gualtieri S, Salvino A, Tassone P, Tagliaferri P. **"A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it?"** J Ovarian Res. 2013 Feb 6;6(1):10.
 111. Rossi M, Pitari MR, Amodio N, Di Martino MT, Conforti F, Leone E, **Botta C**, Paolino FM, Del Giudice T, Iuliano E, Caraglia M, Ferrarini M, Giordano A, Tagliaferri P, Tassone P. **"miR-29b negatively regulates human osteoclastic cell differentiation and function: implications for the treatment of multiple myeloma-related bone disease."** J Cell Physiol. 2013 Jul;228(7):1506-15.
 112. Ciliberto D*, **Botta C***, Correale P, Rossi M, Caraglia M, Tassone P, Tagliaferri P. **"Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: A meta-analysis of randomised trials."** Eur J Cancer. 2012 Sep **(equally contributed)*
 113. **Botta C**, Bestoso E, Apollinari S, Cusi MG, Pastina P, Abbruzzese A, Sperlongano P, Misso G, Caraglia M, Tassone P, Tagliaferri P, Correale P. **"Immune-modulating effects of the newest cetuximab-based chemoimmunotherapy regimen in advanced colorectal cancer patients."** J Immunother. 2012 Jun;35(5):440-7.
 114. Correale P, Rotundo MS, **Botta C**, Del Vecchio MT, Tassone P,

- Tagliaferri P. **"Tumor infiltration by chemokine receptor 7 (CCR7)(+) T-lymphocytes is a favorable prognostic factor in metastatic colorectal cancer."** Oncoimmunology. 2012 Jul 1;1(4):531-532.
115. Correale P, Rotundo MS, **Botta C**, Del Vecchio MT, Ginanneschi C, Licchetta A, Conca R, Apollinari S, De Luca F, Tassone P, Tagliaferri P. **"Tumor infiltration by T lymphocytes expressing chemokine receptor 7 (CCR7) is predictive of favorable outcome in patients with advanced colorectal carcinoma."** Clin Cancer Res. 2012 Feb 1;18(3):850-7
116. Correale P, **Botta C**, Cusi MG, Del Vecchio MT, De Santi MM, Gori Savellini G, Bestoso E, Apollinari S, Mannucci S, Marra M, Abbruzzese A, Aquino A, Turriziani M, Bonmassar L, Caraglia M, Tagliaferri P. **"Cetuximab ± chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro."** Int J Cancer. 2012 Apr 1;130(7)
117. Correale P, **Botta C**, Basile A, Pagliuchi M, Licchetta A, Martellucci I, Bestoso E, Apollinari S, Addeo R, Misso G, Romano O, Abbruzzese A, Lamberti M, Luzzi L, Gotti G, Rotundo MS, Caraglia M, Tagliaferri P. **"Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients."** Cancer Biol Ther. 2011 Jul 15;12(2)

Palermo, June 17, 2026

Cirino Botta